InterOcean Capital Group LLC Purchases 1,291 Shares of Pfizer Inc. (NYSE:PFE)

InterOcean Capital Group LLC raised its position in shares of Pfizer Inc. (NYSE:PFEFree Report) by 5.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 25,864 shares of the biopharmaceutical company’s stock after buying an additional 1,291 shares during the quarter. InterOcean Capital Group LLC’s holdings in Pfizer were worth $745,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of PFE. Seven Mile Advisory boosted its position in shares of Pfizer by 5.4% in the 4th quarter. Seven Mile Advisory now owns 10,455 shares of the biopharmaceutical company’s stock worth $301,000 after purchasing an additional 536 shares in the last quarter. Loews Corp bought a new stake in Pfizer during the 4th quarter valued at about $8,637,000. Certified Advisory Corp raised its holdings in Pfizer by 1.4% in the fourth quarter. Certified Advisory Corp now owns 64,873 shares of the biopharmaceutical company’s stock worth $1,868,000 after buying an additional 887 shares during the last quarter. CNA Financial Corp bought a new position in shares of Pfizer in the fourth quarter worth approximately $8,637,000. Finally, Goodman Financial Corp grew its holdings in shares of Pfizer by 4.6% during the fourth quarter. Goodman Financial Corp now owns 269,706 shares of the biopharmaceutical company’s stock valued at $7,765,000 after buying an additional 11,826 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE:PFE traded down $0.61 on Thursday, reaching $28.99. The company’s stock had a trading volume of 13,368,107 shares, compared to its average volume of 42,254,559. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37. The company has a 50-day simple moving average of $27.24 and a 200 day simple moving average of $27.97.

Pfizer (NYSE:PFEGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.23 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.80%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Analysts Set New Price Targets

Several analysts have commented on the company. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Morgan Stanley upped their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Ten research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $35.86.

Check Out Our Latest Stock Report on Pfizer

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEFree Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.